Jacob J. Smith
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jacob J. Smith has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Abigail Colley
Vaccine and Immunotherapy Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
1 shared publication - Ann E. Sluder
Vaccine and Immunotherapy Center, Massachusetts General Hospital, Boston, MA, United States
1 shared publication - Blanca Pamias‐Lopez
National Heart & Lung Institute Imperial College London London UK
1 shared publication - Cesare Mn Terracciano
National Heart and Lung Institute, Imperial College London, London, United Kingdom
1 shared publication - Daiki Sugita
Vaccine and Immunotherapy Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
1 shared publication Danika Hayman
National Heart & Lung Institute Imperial College London London UK
1 shared publication
Latest Publications
- Open Access
- 24 August 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- p. OF1-OF19
New Therapeutic Cancer Vaccine with Lenalidomide Induces Potent T-cell Immunity and Inhibits HPV E6/E7–Expressing Tumor Growth in Mice
Current prophylactic human papillomavirus (HPV) vaccines prevent infection but have limited therapeutic benefit in established HPV-driven malignancies. To address this unmet need, we developed VTX-067, a modular self-assembling therapeutic cancer vaccine consisting of a recombinant Mycobacterium tuberculosis heat shock protein 70–avidin fusion (MAV) noncovalently bound to biotinylated HPV E6/E7 MHC class I– and II–restricted peptide concatemers. MAV is produced in Chinese hamster ovary cells with minimal endotoxin. Assembled VTX-067 is designed to elicit both CD4+ and CD8+ T-cell responses against HPV-associated tumors. In multiple tumor models expressing HPV E6/E7, intradermal vaccination with VTX-067 induced potent and dose-dependent HPV E6/E7–specific CD8+ and CD4+ T-cell responses without evidence of local reactogenicity. Therapeutic vaccination significantly delayed subcutaneous tumor progression, extended survival, and provided durable protection against tumor rechallenge. VTX-067 treatment increased intratumoral CD8+ T-cell infiltration, elevated the CD8:regulatory T-cell ratio, and upregulated a Th1/cytotoxic transcriptional program, including Ifnγ, Tbx21, Stat1, and granzyme B. Depletion of CD8+ T cells eliminated vaccine efficacy, whereas adoptive transfer of VTX-067–primed CD8+ T cells conferred tumor protection in recipient mice. In a cervicovaginal orthotopic model, both intradermal and intramucosal administration generated systemic E6/E7-specific effector responses and sustained control of mucosal tumors. Notably, combining a suboptimal VTX-067 dose with the immunomodulatory agent lenalidomide further enhanced tumor control and survival, demonstrating a potential dose-sparing strategy. These findings establish VTX-067 as a safe, highly immunogenic therapeutic vaccine with CD8+ T cell–dependent antitumor activity and support its clinical development alone or in combination with immune-modulating agents for HPV-associated cancers.
- 24 August 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- p. OF1-OF19
Open AccessNew Therapeutic Cancer Vaccine with Lenalidomide Induces Potent T-cell Immunity and Inhibits HPV E6/E7–Expressing Tumor Growth in Mice
Current prophylactic human papillomavirus (HPV) vaccines prevent infection but have limited therapeutic benefit in established HPV-driven malignancies. To address this unmet need, we developed VTX-067, a modular self-assembling therapeutic cancer vaccine consisting of a recombinant Mycobacterium tuberculosis heat shock protein 70–avidin fusion (MAV) noncovalently bound to biotinylated HPV E6/E7 MHC class I– and II–restricted peptide concatemers. MAV is produced in Chinese hamster ovary cells with minimal endotoxin. Assembled VTX-067 is designed to elicit both CD4+ and CD8+ T-cell responses against HPV-associated tumors. In multiple tumor models expressing HPV E6/E7, intradermal vaccination with VTX-067 induced potent and dose-dependent HPV E6/E7–specific CD8+ and CD4+ T-cell responses without evidence of local reactogenicity. Therapeutic vaccination significantly delayed subcutaneous tumor progression, extended survival, and provided durable protection against tumor rechallenge. VTX-067 treatment increased intratumoral CD8+ T-cell infiltration, elevated the CD8:regulatory T-cell ratio, and upregulated a Th1/cytotoxic transcriptional program, including Ifnγ, Tbx21, Stat1, and granzyme B. Depletion of CD8+ T cells eliminated vaccine efficacy, whereas adoptive transfer of VTX-067–primed CD8+ T cells conferred tumor protection in recipient mice. In a cervicovaginal orthotopic model, both intradermal and intramucosal administration generated systemic E6/E7-specific effector responses and sustained control of mucosal tumors. Notably, combining a suboptimal VTX-067 dose with the immunomodulatory agent lenalidomide further enhanced tumor control and survival, demonstrating a potential dose-sparing strategy. These findings establish VTX-067 as a safe, highly immunogenic therapeutic vaccine with CD8+ T cell–dependent antitumor activity and support its clinical development alone or in combination with immune-modulating agents for HPV-associated cancers.
- Open Access
- 17 October 2023
- Published by Wiley in Experimental Physiology
- Vol. 109 (3) , 405-415
MyoLoop: Design, development and validation of a standalone bioreactor for pathophysiological electromechanical in vitro cardiac studies
Mechanical load is one of the main determinants of cardiac structure and function. Mechanical load is studied in vitro using cardiac preparations together with loading protocols (e.g., auxotonic, isometric). However, such studies are often limited by reductionist models and poorly simulated mechanical load profiles. This hinders the physiological relevance of findings. Living myocardial slices have been used to study load in vitro. Living myocardial slices (LMS) are 300‐μm‐thick intact organotypic preparations obtained from explanted animal or human hearts. They have preserved cellular populations and the functional, structural, metabolic and molecular profile of the tissue from which they are prepared. Using a three‐element Windkessel (3EWK) model we previously showed that LMSs can be cultured while performing cardiac work loops with different preload and afterload. Under such conditions, LMSs remodel as a function of the mechanical load applied to them (physiological load, pressure or volume overload). These studies were conducted in commercially available length actuators that had to be extensively modified for culture experiments. In this paper, we demonstrate the design, development and validation of a novel device, MyoLoop. MyoLoop is a bioreactor that can pace, thermoregulate, acquire and process data, and chronically load LMSs and other cardiac tissues in vitro. In MyoLoop, load is parametrised using a 3EWK model, which can be used to recreate physiological and pathological work loops and the remodelling response to these. We believe MyoLoop is the next frontier in basic cardiovascular research enabling reductionist but physiologically relevant in vitro mechanical studies.
- 17 October 2023
- Published by Wiley in Experimental Physiology
- Vol. 109 (3) , 405-415
Open AccessMyoLoop: Design, development and validation of a standalone bioreactor for pathophysiological electromechanical in vitro cardiac studies
Mechanical load is one of the main determinants of cardiac structure and function. Mechanical load is studied in vitro using cardiac preparations together with loading protocols (e.g., auxotonic, isometric). However, such studies are often limited by reductionist models and poorly simulated mechanical load profiles. This hinders the physiological relevance of findings. Living myocardial slices have been used to study load in vitro. Living myocardial slices (LMS) are 300‐μm‐thick intact organotypic preparations obtained from explanted animal or human hearts. They have preserved cellular populations and the functional, structural, metabolic and molecular profile of the tissue from which they are prepared. Using a three‐element Windkessel (3EWK) model we previously showed that LMSs can be cultured while performing cardiac work loops with different preload and afterload. Under such conditions, LMSs remodel as a function of the mechanical load applied to them (physiological load, pressure or volume overload). These studies were conducted in commercially available length actuators that had to be extensively modified for culture experiments. In this paper, we demonstrate the design, development and validation of a novel device, MyoLoop. MyoLoop is a bioreactor that can pace, thermoregulate, acquire and process data, and chronically load LMSs and other cardiac tissues in vitro. In MyoLoop, load is parametrised using a 3EWK model, which can be used to recreate physiological and pathological work loops and the remodelling response to these. We believe MyoLoop is the next frontier in basic cardiovascular research enabling reductionist but physiologically relevant in vitro mechanical studies.